概要

DNDi operates through a virtual model whereby all of its R&D activities are outsourced, contributing to keep development costs under control, while providing a high level of flexibility. As a consequence of this strategic option, the development of an efficient drug development programme to address neglected diseases requires the establishment of strong agreements within the entire biomedical landscape, so as to leverage and mobilise private and public sector resources.

However, owing to the absence of foreseeable profit in the field of neglected tropical diseases, the business drivers of these partnerships are intrinsically different from those of the lucrative-driven contracts the drug industry is accustomed to.

Successful partnership agreements require the management of divergent interests by solving critical issues like licensing rights, confidentiality concerns, intellectual property (IP) management, and/or lack of a visible profit.

DNDi has developed various models of collaboration successfully managing the respective interest of the partners, so as to reach well balanced agreements. Defining the field (the diseases), territory (the geographical area), and the market (public vs. private distribution) are important issues that must be agreed upon by both parties in order for a private partner to provide DNDi access to a compound or technology.

Having recently signed key, multi-year commitments with various partners who will serve as cornerstones in support of our pipeline, DNDi continues to identify and engage partners who share our vision and commitment, and ensures that a well-balanced pipeline is established for the 3 diseases of primary focus: sleeping sickness (HAT), visceral leishmaniasis (VL), and Chagas disease.

Please contact us at このメールアドレスは、スパムロボットから保護されています。アドレスを確認するにはJavaScriptを有効にしてください This e-mail address is being protected from spambots. You need JavaScript enabled to view it to propose collaborative projects.